Regulatory dysfunction in leukotaxis.

The chemotactic factor inactivator (CFI) in human serum appears to have important regulatory function in the inflammatory response. In humans with elevated serum levels of CFI, defective mobilization of leukocytes in vivo has been noted, both in skin windows and in skin testing with various antigens. In experimental immune complex-induced acute inflammatory reactions in rat skin and lung, purified human CFI at very low doses has potent antiinflammatory effects and is able to suppress permeability changes, neutrophil infiltration, and hemorrhage, all of which are dependent initially on the role of leukotactic mediators.

[1]  P. Ward,et al.  Suppression of immune complex-induced inflammation by the chemotactic factor inactivator. , 1977, The Journal of clinical investigation.

[2]  P. Ward,et al.  Release of a leukotactic inhibitor from phagocytizing leukocytes , 1977 .

[3]  P. Ward,et al.  Characterization of the protease activity in the chemotactic factor inactivator. , 1976, The Journal of clinical investigation.

[4]  P. Ward,et al.  Defective leukotaxis in patients with lepromatous leprosy. , 1976, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[5]  A. Degraff,et al.  Leukotactic Dysfunction in Sarcoidosis , 1976 .

[6]  P. Ward,et al.  Antileukotactic properties of tumor cells. , 1975, The Journal of clinical investigation.

[7]  P. Ward,et al.  Defective regulation of chemotaxis in cirrhosis. , 1975, The Journal of laboratory and clinical medicine.

[8]  P. Ward,et al.  Two distinct chemotactic factor inactivators in human serum. , 1975, Journal of immunology.

[9]  P. Ward,et al.  Acute immunologic pulmonary alveolitis. , 1974, The Journal of clinical investigation.

[10]  P. Ward,et al.  Defective regulation of inflammatory mediators in Hodgkin's disease. Supernormal levels of chemotactic-factor inactivator. , 1974, The New England journal of medicine.

[11]  P. Ward,et al.  Chemotactic factor inactivator in normal human serum. , 1973, The Journal of clinical investigation.

[12]  P. Ward,et al.  Biologic role of complement products. Complement-derived leukotactic activity extractable from lesions of immunologic vasculitis. , 1972, Journal of immunology.

[13]  P. Ward.  Biological activities of the complement system. , 1972, Annals of allergy.

[14]  F. Rosen,et al.  Genetic aspects of the complement system. , 1971, Advances in immunology.

[15]  H. Müller-Eberhard,et al.  Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. , 1970, The Journal of clinical investigation.